Neuromuscular Blocking Agents

NMBAs Overview - Blocking the Signal

Neuromuscular Blocking Agents (NMBAs) induce reversible muscle paralysis for procedures (intubation, surgery) by acting at the Neuromuscular Junction (NMJ).

• Target: Postsynaptic nicotinic acetylcholine receptors ($nAChR$) on the motor endplate.
• Action: Prevent acetylcholine ($ACh$) from binding or activating $nAChR$, inhibiting muscle depolarization and causing flaccid paralysis.
• Classification:
  • Depolarizing:
    • e.g., Succinylcholine.
    • $nAChR$ agonist: initial depolarization (fasciculations) then prolonged block.
  • Non-depolarizing:
    • e.g., Rocuronium, Vecuronium.
    • Competitive $nAChR$ antagonists: direct paralysis, no fasciculations.

⭐ Succinylcholine (depolarizing) uniquely causes initial muscle fasciculations before paralysis; non-depolarizing agents do not.

Succinylcholine - The Fast & Furious Blocker

• Type: Depolarizing NMB; only one in class.
• Mechanism: AChR agonist at NMJ.
  • Phase I: Fasciculations → paralysis. AChE inhibitors worsen.
  • Phase II (high/repeat dose): NDMB-like block.
• Kinetics:
  • Onset: 30-60s. Duration: 5-10min.
  • Metabolism: Plasma pseudocholinesterase.
• Dose (IV): 1-1.5 mg/kg.
• Use: Rapid Sequence Intubation (RSI).
• Side Effects:
  • Fasciculations, myalgia.
  • Hyperkalemia ⚠️ (burns >24h, trauma, denervation).
  • ↑IOP, ↑gastric pressure.
  • Malignant Hyperthermia (MH) trigger ⚠️.
  • Bradycardia (children, repeat doses).
  • Prolonged block: pseudocholinesterase deficiency (Dibucaine #).

⭐ Critical risk: severe hyperkalemia in patients with burns (>24-48h), crush injuries, or denervating neuromuscular diseases.

Non-Depolarizing Agents - The Steady Crew

• Mechanism: Competitive antagonists at nAChRs (NMJ). Prevent ACh binding → no depolarization.

• Key Agents:

  Agent	Class	Duration	Metabolism/Elimination	Notes
  Atracurium	Benzylisoquinolinium	Intermediate	Hofmann elim., ester hydrolysis	Can cause histamine release; Laudanosine metabolite
  Cisatracurium	Benzylisoquinolinium	Intermediate	Hofmann elim. (organ-independent)	Minimal histamine; No direct renal/hepatic metabolism
  Mivacurium	Benzylisoquinolinium	Short	Plasma pseudocholinesterase	Histamine release; duration prolonged if atypical enzyme
  Pancuronium	Aminosteroid	Long	Renal excretion (primarily)	Vagolytic (↑HR, ↑BP); active metabolites
  Vecuronium	Aminosteroid	Intermediate	Hepatic metabolism (primarily)	Cardiovascularly stable; no histamine release
  Rocuronium	Aminosteroid	Intermediate	Hepatic metabolism (primarily)	Fastest onset of non-depolarizers; minimal histamine

• General:

  • Slower onset vs Succinylcholine (except high-dose Rocuronium).
  • No fasciculations. 📌
  • Reversal: Anticholinesterases (e.g., Neostigmine + Glycopyrrolate).
  • Specific Reversal: Sugammadex for Rocuronium & Vecuronium.
  • Monitor: Train-of-Four (TOF).

⭐ Cisatracurium: Preferred in renal/hepatic failure due to organ-independent Hofmann elimination.

Reversal & Monitoring - Waking Up & Watching Out

• Reversal Strategies:
  • Anticholinesterases:
    • Neostigmine: 0.04-0.07 mg/kg. Onset 5-10 min.
    • Pair with Glycopyrrolate (0.01-0.02 mg/kg) to counter muscarinic effects. 📌 Neo+Glyco: Slower onsets match.
  • Sugammadex (SRBA):
    • For Rocuronium/Vecuronium.
    • Dose: 2 mg/kg (TOF count ≥2), 4 mg/kg (PTC 1-2), 16 mg/kg (immediate reversal of Rocuronium 1.2 mg/kg).
• Neuromuscular Monitoring (PNS):
  • Site: Ulnar nerve (Adductor Pollicis).
  • Train-of-Four (TOF):
    • TOF Ratio (T4/T1) target > 0.9 for safe extubation.
  • Double Burst Stimulation (DBS): Easier manual fade detection.
  • Post-Tetanic Count (PTC): For deep blocks (no TOF response).
• Waking Up & Watching Out:
  • Prevent Residual Neuromuscular Blockade (RNMB): TOF ratio < 0.9. Risks: aspiration, hypoxia.
  • Objective monitoring (e.g., acceleromyography) is preferred.

⭐ Quantitative monitoring (e.g., acceleromyography) showing a TOF ratio > 0.9 is the gold standard for confirming adequate recovery from NMBAs and readiness for extubation.

High‑Yield Points - ⚡ Biggest Takeaways

• Succinylcholine: Rapid onset/offset; triggers malignant hyperthermia, risk of hyperkalemia.
• Non-depolarizers: Competitive ACh antagonists; reversed by Neostigmine/Glycopyrrolate or Sugammadex (for rocuronium/vecuronium).
• Atracurium/Cisatracurium: Hoffmann elimination; Cisatracurium has less histamine release.
• Rocuronium: Alternative for Rapid Sequence Intubation (RSI).
• Pancuronium: Long-acting; causes tachycardia (vagolytic).
• Monitor with Train-of-Four (TOF); aim for 1-2 twitches.
• Block potentiation: Inhalational agents, aminoglycosides, hypothermia, acidosis.